Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period.

Florentino, PTORCID logo; Alves, FJORCID logo; Cerqueira-Silva, TORCID logo; Oliveira, VdAORCID logo; Júnior, JB; Jantsch, AG; Penna, GOORCID logo; Boaventura, V; Werneck, GLORCID logo; Rodrigues, LC; +4 more...Pearce, NORCID logo; Barral-Netto, MORCID logo; Barreto, ML; Paixão, ESORCID logo and (2022) Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nature communications, 13 (1). 4756-. DOI: 10.1038/s41467-022-32524-5
Copy

Although severe COVID-19 in children is rare, they may develop multisystem inflammatory syndrome, long-COVID and downstream effects of COVID-19, including social isolation and disruption of education. Data on the effectiveness of the CoronaVac vaccine is scarce during the Omicron period. In Brazil, children between 6 to 11 years are eligible to receive the CoronaVac vaccine. We conducted a test-negative design to estimate vaccine effectiveness using 197,958 tests from January 21, 2022, to April 15, 2022, during the Omicron dominant period in Brazil among children aged 6 to 11 years. The estimated vaccine effectiveness for symptomatic infection was 39.8% (95% CI 33.7-45.4) at ≥14 days post-second dose. For hospital admission vaccine effectiveness was 59.2% (95% CI 11.3-84.5) at ≥14 days. Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness.


picture_as_pdf
Florentino_etal_2022_Vaccine-effectiveness-of-CoronaVac-against.pdf
subject
Published Version
Available under Creative Commons: Attribution 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads